Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy

NCT01047501 is registered in ClinicalTrials.gov with Amarin Pharma Inc. as lead sponsor.

NCT NCT01047501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01047501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy
Lead sponsor
Amarin Pharma Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2009
Completion date
February 28, 2011
Enrollment
702 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia